Basle, Switzerland
September 22, 2008
Genedata, the leading provider of in-silico solutions for
pharmaceutical R&D and related life sciences, today announced
the release of Genedata Screener® 6.0, the latest version of its
open and scalable enterprise solution for high throughput
screening (HTS) and high content screening (HCS) analysis.
Screener 6.0 combines an enterprise-wide assay data management
platform with high-performance processing workflows and flexible
analysis tools and has a special focus on time series data
analysis.
Time series data is complex with hundreds of values per well.
Sensible data aggregation is needed to derive meaningful results
from such time-dependent responses. The latest Screener release
includes an enhanced solution to these kinetics assay data
management challenges. This new functionality enables users to
rapidly analyze, integrate and manage extensive sets of time
series data, independent of instrumentation, technology, volume
or location.
In the Kinetics Assay module users can optimize aggregation
rules, re-analyze data for complete campaigns and systematically
gather mechanistic information from curve shape in addition to
amplitude. The application programming interfaces (APIs)
included in this open system can be easily connected to the many
different readers already on the market, as well as implemented
to provide custom aggregation functions for specific
experiments. Quality assessment and visualization are vastly
improved and interferences with biological response can be
identified from kinetics traces. With consistent data management
and visualization, the resulting parameters are optimized for
each assay and users are able to extract more information to get
better results and better qualified hits from each single
experiment.
“Genedata Screener is already licensed by the top
pharmaceutical, agrochemical and life science biotech companies
worldwide,” said Dr. Othmar Pfannes, CEO of Genedata. “With the
addition of the Kinetics Analyzer module, Screener 6.0 extends
the use of our enterprise high throughput and high content
screening platform to the rapidly growing market of time series
data analysis. More than ever before research groups spanning
the globe can easily analyze, manage and share complex data
regardless of the instrumentation they use.”
Genedata develops and globally markets sophisticated
computational solutions for drug discovery and related research
processes in the life sciences. Genedata’s solutions enable
scientists to process, integrate, analyze, and manage large and
complex experimental data sets generated by high-throughput
technologies. Our solutions include Genedata Phylosopher® for
target discovery and integrative biological data management,
Genedata Screener® for automated high throughput screening and
high content screening, and Genedata Expressionist® for
biomarker discovery and personalized medicine. Founded in 1997,
Genedata is privately held, with headquarters in Basel,
Switzerland, and offices in Boston & San Francisco, USA,
Konstanz & Munich, Germany and Tokyo, Japan. |
|
